Navigation Links
Rheumatoid Arthritis Market Forecast
Date:9/20/2011

ile safety is a concern for new drugs, the deaths mirror those seen in the era prior to biologics. Datamonitor forecasts favorable uptake of tofacitinib, reaching sales of $1.2bn by 2020 in the major markets.Opinion leaders verify rising interest to adopt non-TNF biologics earlier in the algorithm, due to familiarity and more experience of their side-effects. With Bristol-Myers Squibb gaining US approval of subcutaneous Orencia (abatacept) in July 2011, this reformulation adds positively to its lifecycle and it will benefit from this projected trend.What impact has the deaths in a Phase III trial of tofactinib had on its potential future uptake across the seven major rheumatoid arthritis markets?What is the future outlook in terms of patients and sales for 2009 market entrants Cimzia and Simponi and how does this compare to older TNF brands?How will the launch of subcutaneous formulations of marketed intravenous drugs Orencia and Actemra change their usage and impact future brand sales?How will first-, second-, third- and fourth-line and beyond biologic brand dynamics change in the rheumatoid arthritis markets over the coming decade?How will each of the seven major markets (the US, Japan, France, Germany, Italy, Spain and the UK) evolve in terms of patients from 2010 to 2020?

To order this report:

Pathology Industry: Rheumatoid Arthritis Market Forecast

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
2. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
3. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
4. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
5. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
6. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
7. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
8. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
9. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
10. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
(Date:8/30/2014)... 30, 2014 Seniors Guide, the comprehensive guide ... focus on Alzheimer’s Disease, Dementia, and Memory Loss . ... public of being diagnosed with the Alzheimer’s, inspired Seniors Guide ... Be Me”. The movie, out on October 14, 2014, ... his diagnosis of the disease – which inspires a final ...
(Date:8/30/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... lead extraction (TLE) is clinically successful in more than ... Lead Extraction ConTRolled (ELECTRa) registry presented for the first ... Grazia Bongiorni, chair of the registry,s executive committee. , ... devices (CIED) implant procedures has grown in recent years. ... increased and leads are often the cause. TLE is ...
(Date:8/30/2014)... The new review published by Daily Gossip reveals ... Brimeyer, who wanted to make her guide accessible to sufferers ... now easy to find in the form of an eBook, ... author of the new method shares all her tips and ... in its review that the leaky gut syndrome can be ...
Breaking Medicine News(10 mins):Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2
... 7 MQ Associates, Inc.,("MedQuest"), a leading national provider ... third quarter and nine months ended,September 30, 2007. ... 2007, representing,a decrease of $8.1 million, or 11.9%, from ... Net revenue was $186.5 million for the nine months,ended ...
... for retinopathy laser treatment, study finds , WEDNESDAY, Nov. ... diabetes, the drug fenofibrate reduces the need for laser ... loss and blindness among working-age adults worldwide. , Australian ... ages 50-75, who received either 200 milligrams per day ...
... 7 MED3OOO, Inc., a national healthcare,management ... Molina,Healthcare of California to provide Revenue Cycle ... communications technology, and,coding services. Molina Healthcare ... managed,healthcare companies serving patients who have traditionally ...
... BURLINGTON, Mass., Nov. 7 LeMaitre Vascular,Inc. (Nasdaq: ... medical,devices and implants for the treatment of peripheral ... Adams inaugural Cardiovascular,Conference on Tuesday, November 13, 2007, ... David B. Roberts, President of LeMaitre Vascular, ...
... Changes reflect company,s focus on growth and value ... Technologies, Inc. ("EAU",or "Company") (OTC Bulletin Board: EAUI), ... Technology" to numerous industries,including food processing, agriculture, dairy ... help the organization,better meet the needs of its ...
... cholesterol-lowering drug appears to disrupt sleep patterns of some ... Sessions 2007. , The findings are significant because sleep ... adverse health consequences, such as promoting weight gain and ... the study and an associate professor of medicine and ...
Cached Medicine News:Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 2Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 3Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 4Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 5Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 6Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 7Health News:Diabetes Drug Helps Protect Patients' Eyes 2Health News:Molina Medical Group Selects MED3OOO 2Health News:EAU Technologies Announces New Chairman of the Board and Board Leadership 2Health News:EAU Technologies Announces New Chairman of the Board and Board Leadership 3Health News:EAU Technologies Announces New Chairman of the Board and Board Leadership 4Health News:Cholesterol-lowering drug linked to sleep disruptions 2
... cannula with 30 gauge, 4.76 mm tip is ... Cannula is attached to a luer lock high ... inch long), for use with high viscosity substances. ... using visco elastic materials. Flattened, angled tip of ...
20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
The moist air humidifying chamber is designed for the infusion of humidified air during phakic fluid air exchange. Sterile single-use. 10 per box. Most popular size or model....
Medicine Products: